文献速递临床试验与 GCP

角膜塑形镜联合0.01%阿托品控制近视的疗效:一项随机对照双盲多中心试验的研究方案

Efficacy of combined orthokeratology and 0.01% atropine for myopia control: the study protocol for a randomized, controlled, double-blind, and multicenter trial.
PubMed 文献 · Trials · 2021-12-01

本研究为随机对照双盲多中心试验,拟招募96名8-12岁儿童,比较角膜塑形镜联合0.01%阿托品滴眼液与角膜塑形镜联合安慰剂滴眼液在控制近视进展和眼轴增长方面的疗效差异。主要结局为随机化后24个月时两组间眼轴长度相对基线的变化差值,随访时间点为1、6、12、18和24个月。

要点

  • 纳入标准为任一眼近视度数在-1.00至-4.00 D之间,散光不超过1.50 D。
  • 共96名8-12岁儿童,每组48人,分别接受角膜塑形镜联合0.01%阿托品或联合安慰剂治疗。
  • 主要结局为随机化后24个月时两组间眼轴长度相对基线的变化差值。

核心结论

  • 本研究旨在比较角膜塑形镜联合0.01%阿托品与单用角膜塑形镜在儿童近视控制中的疗效。

研究设计与样本

  • 随机、对照、双盲、多中心临床试验,共招募96名8-12岁儿童,每组48人,分别接受角膜塑形镜联合0.01%阿托品滴眼液或角膜塑形镜联合安慰剂滴眼液治疗,随访时间点为随机化后1、6、12、18和24个月。

关键数值与推荐

  • 纳入标准:任一眼近视度数在-1.00至-4.00 D之间,散光不超过1.50 D。
  • 主要结局:随机化后24个月时两组间眼轴长度相对基线的变化差值。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The prevalence of myopia is increasing worldwide and is presently recognized as a major public health issue. Researchers and clinicians have been devoted in exploring appropriate clinical interventions to slow its progression in children. Mounting publications have proven that both orthokeratology (OK lens) and 0.01% atropine eyedrop can retard eye growth and myopia progression. However, it remains unclear whether the combination of OK lens and 0.01% atropine has the potential to magnify the effectiveness of myopia control. The present study aims to compare the myopia control efficiency of the combination of OK lens and 0.01% atropine with the monotherapy of OK lens in children. METHODS: The present study is a randomized, controlled, double-blind and multicenter clinical trial. A total of 96 children within 8-12 years old were recruited. These participants are treated with the combination of OK lens and 0.01% atropine eyedrop or the combination of OK lens and placebo eyedrop. Each group includes 48 participants. The inclusion criteria are as follows: myopia between - 1.00 and - 4.00 D in either eye and astigmatism of no more than 1.50 D. The follow-up time points will be 1, 6, 12, 18, and 24 months from randomization. The primary outcome is determined by the difference in axial length of the two groups, between the baseline and 24 months from randomization. DISCUSSION: The present randomized, controlled clinical trial would indicate the additive effects of the combination of OK lens and 0.01% atropine, and the extent of these effects, in retarding myopia progression and axial elongation in children. TRIAL REGISTRATION: Chinese Clinical Trial Registry (ChiCTR), ChiCTR1800018419 . Registered on 17 September 2018. http://www.chictr.org.cn/showproj.aspx?proj=29216.

来源:Trials,查看原文。版权归原作者所有。

引用

  1. Yuan Y, Zhu C, Liu M, et al. Efficacy of combined orthokeratology and 0.01% atropine for myopia control: the study protocol for a randomized, controlled, double-blind, and multicenter trial. Trials. 2021. PMID: 34852833. doi:10.1186/s13063-021-05825-1

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。